Viridian Therapeutics, Inc.\De (VRDN) Stock Price & Analysis
Viridian Therapeutics, Inc.\De (VRDN) rose 3.69% to USD 16.31 as of June 10, 2026 at 02:15 UTC, according to Nexqual real-time market data.
VRDN last closed at USD 15.73; the session ranged USD 15.67–16.47 on volume of 1,174,970 shares. Market capitalization is $1.80B, with a 52-week range of USD 13.18–34.29 (NCM). Source: Nexqual, June 10, 2026 at 02:15 UTC.
Key Statistics (as of June 10, 2026 at 02:15 UTC)
| Price | USD 16.31 |
|---|---|
| Change | ▲ 3.69% (up) |
| Previous Close | USD 15.73 |
| Open | USD 15.96 |
| Day Range | USD 15.67 – 16.47 |
| 52-Week Range | USD 13.18 – 34.29 |
| Volume | 1,174,970 shares |
| Market Cap | $1.80B |
| Exchange | NCM |
Technical Analysis (VRDN)
Nexqual's technical model rates VRDN "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:15 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.37 (neutral) |
| vs SMA50 | Above (USD 15.97) |
| MACD | -0.21 (negative) |
Analyst Ratings (VRDN)
Wall Street analysts rate VRDN "Strong Buy" based on 16 analysts, with a mean price target of USD 33.94 (range USD 20–50), per Nexqual as of June 10, 2026 at 02:15 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 33.94 |
| High Target | USD 50 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 16 / 1 / 0 |
Earnings (VRDN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.04 |
| Revenue Estimate | $26,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.9 vs est -1.08 ▲ beat |
| 2025-12-31 | USD -1.08 vs est -1 ▼ miss |
| 2025-09-30 | USD -0.34 vs est -0.94 ▲ beat |
| 2025-06-30 | USD -1 vs est -0.98 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financials & Fundamentals (VRDN)
| Total Revenue | $70.92M |
|---|---|
| Revenue Growth (YoY) | +95.80% |
| Gross Margin | +0.00% |
| Operating Margin | -82389.36% |
| Profit Margin | +0.00% |
| ROE | -58.14% |
| Debt / Equity | 8.39 |
| Current Ratio | 15.15 |
| Total Cash | $762.18M |
| Total Debt | $53.35M |
| Free Cash Flow | $-182.55M |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financial Health Score (VRDN)
Nexqual rates Viridian Therapeutics, Inc.\De's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:15 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $762M cash vs $53M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$183M, burning cash |
| Efficiency | Critical — ROE -58%, ROA -33.3% |
Ownership (VRDN)
| Insider Ownership | +0.14% |
|---|---|
| Institutional Ownership | +109.82% |
| Shares Outstanding | 110.43M |
| Float | 103.02M |
| Short % of Float | +13.71% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Leadership (VRDN)
Viridian Therapeutics, Inc.\De is led by Stephen F. Mahoney (age 54), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:15 UTC.
| CEO, President & Director | Stephen F. Mahoney (age 54) |
|---|---|
| Chief Financial Officer | Seth Harmon (age 44) |
| Chief Operating Officer | Thomas W. Beetham (age 55) |
| Co-Founder & Chairman of Scientific Advisory Board | Eric N. Olson |
Major Backers & Investors (VRDN)
Notable institutional backers of Viridian Therapeutics, Inc.\De include FMR, LLC, Fidelity, Bellevue Group AG, according to Nexqual as of June 10, 2026 at 02:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.92% |
| Fidelity | 6.71% |
| Bellevue Group AG | 6.53% |
| Fairmount Funds Management LLC | 3.8% |
| Venrock Adviser, LLC | 3.77% |
| Price (T.Rowe) Associates Inc | 3.11% |
| Paradigm Biocapital Advisors LP | 3.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.45% |
| Vanguard Group | 7.98% |
| State Street | 7.39% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
From Viridian Therapeutics, Inc.\De's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
- It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
- The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.
- Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| VERA | Vera Therapeutics, Inc. | USD 31.81 | ▼ 1.49% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:15 UTC. This page is informational and not investment advice.